Program
maridebart cafraglutide
Also written as “Maridebart Cafraglutide”, “Maridebart cafraglutide” and “AMG 133”.
Its studies are mostly in Obesity · Diabetes Mellitus, Type 2 · Atherosclerosis · Sleep Apnea, Obstructive · Liver Diseases, led by Amgen.
Drug pageMaridebart cafraglutide: every studyAll 32 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Amgen | 3219 open or running | phase 3since Feb 28, 2025 | Jul 16, 2020 | Nov 18, 2026phase 1 · NCT07523711 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Not listed one by one: 11 earlier studies, Jul 16, 2020 to Jun 16, 2025.
- Jan 19, 2023Named maridebart cafraglutideINNProposed as its International Nonproprietary Name in WHO's List 128 · before, AMG 133
- Aug 29, 2025Phase 1 study in Diabetes Mellitus, Type 2NCT07160257 · 56 enrolled · United States
- Nov 5, 20252 phase 3 studiesNCT07225686, NCT07226765
- Nov 7, 20252 phase 1 studies in OverweightNCT07226778, NCT07229157
- Dec 16, 20252 phase 1 studies in OverweightNCT07310563, NCT07313761
- Feb 6, 2026Phase 2 study in OverweightNCT07441252 · 180 enrolled · United States
- Feb 18, 20263 phase 1 studiesNCT07429045, NCT07429032, NCT07428525
- Apr 6, 2026Phase 1 study in OverweightNCT07523711 · 49 enrolled · United States
- May 4, 2026Phase 3 study in ObesityNCT07575399 · 300 planned · United States, Puerto Rico
- Jun 29, 20262 phase 3 studies in ObesityNCT07684235, NCT07684144
- Jul 16, 2026Phase 1 study in OverweightNCT07717814 · 154 enrolled · United States
- Sep 16, 2026Phase 1 study in OverweightNCT07832799 · 340 planned
- Oct 5, 20262 phase 3 studiesNCT07866066, NCT07871409
- Oct 27, 2026Phase 1 study in ObesityNCT07908316 · 180 planned · United States
- Nov 2, 2026Phase 1 study in ObesityNCT07921316 · 356 planned
Ahead
- Nov 15, 2026Primary completion: phase 1 study in Diabetes Mellitus, Type 2NCT07160257
- Nov 18, 2026Primary completion: phase 1 study in OverweightNCT07523711
- Jan 21, 2027Primary completion: phase 3 study in Diabetes Mellitus, Type 2NCT06858878
- Jan 21, 2027Primary completion: phase 3 study in ObesityNCT06858839
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 32 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07921316Obesity | 1 | Not yet recruiting | Jul 26, 2027 | 356 |
| NCT07908316Obesity · United States | 1 | Recruiting | Dec 20, 2027 | 180 |
| NCT07871409Obesity · United States, Puerto Rico | 3 | Recruiting | Jun 16, 2027 | 230 |
| NCT07866066Diabetes Mellitus, Type 2 · United States, Canada | 3 | Recruiting | Sep 6, 2028 | 1,300 |
| NCT07832799Overweight | 1 | Not yet recruiting | Mar 23, 2027 | 340 |
| NCT07717814Overweight · United States | 1 | Completed | May 22, 2025 | 154 |
| NCT07684235Obesity · United States, Australia, Canada and more | 3 | Recruiting | Dec 26, 2027 | 3,200 |
| NCT07684144Obesity · United States, Canada, Japan and more | 3 | Recruiting | Dec 26, 2027 | 950 |
| NCT07575399Obesity · United States, Puerto Rico | 3 | Recruiting | Jan 3, 2028 | 300 |
| NCT07523711Overweight · United States | 1 | Active, not recruiting | Nov 18, 2026 | 49 |
| NCT07428525Liver Diseases · United States | 1 | Completed | Feb 26, 2026 | 36 |
| NCT07429045Overweight · United States | 1 | Completed | Nov 21, 2025 | 44 |
| NCT07429032Overweight · United States | 1 | Completed | Nov 26, 2025 | 57 |
| NCT07441252Overweight · United States | 2 | Active, not recruiting | Aug 25, 2027 | 180 |
| NCT07313761Overweight · United States | 1 | Completed | Jul 2, 2026 | 349 |
| NCT07310563Overweight · United States | 1 | Completed | May 9, 2025 | 59 |
| NCT07229157Overweight · United States | 1 | Completed | Aug 27, 2026 | 81 |
| NCT07226778Overweight · United States | 1 | Completed | May 28, 2026 | 348 |
| NCT07226765Sleep Apnea, Obstructive · United States, Australia, Brazil and more | 3 | Active, not recruiting | Aug 30, 2027 | 250 |
| NCT07225686Obesity · United States, Australia, Brazil and more | 3 | Active, not recruiting | Aug 20, 2027 | 250 |
| NCT07160257Diabetes Mellitus, Type 2 · United States | 1 | Active, not recruiting | Nov 15, 2026 | 56 |
| NCT07037459Obesity · United States, Argentina, Australia and more | 3 | Recruiting | Jun 30, 2028 | 5,056 |
| NCT07037433Atherosclerosis · United States, Argentina, Australia and more | 3 | Active, not recruiting | Jun 30, 2028 | 12,800 |
| NCT06976372Overweight · United States | 1 | Completed | Dec 27, 2024 | 120 |
| NCT06987695Overweight · Japan | 3 | Active, not recruiting | Apr 27, 2027 | 279 |
| NCT06858878Diabetes Mellitus, Type 2 · United States, Argentina, Bulgaria and more | 3 | Active, not recruiting | Jan 21, 2027 | 1,105 |
| NCT06858839Obesity · United States, Argentina, Australia and more | 3 | Active, not recruiting | Jan 21, 2027 | 3,853 |
| NCT06660173Diabetes Mellitus, Type 2 · United States, Austria, Greece and more | 2 | Active, not recruiting | Oct 6, 2025 | 409 |
| NCT06352892Obesity · Hong Kong | 1 | Completed | Aug 27, 2024 | 20 |
| NCT05669599Obesity · United States, Australia, Canada and more | 2 | Completed | Oct 8, 2024 | 592 |
| NCT05056246Healthy Participants · United States | 1 | Completed | Apr 8, 2022 | 34 |
| NCT04478708Obesity · United States | 1 | Completed | Nov 18, 2022 | 110 |
How it is read
Names in the registry
- “Maridebart Cafraglutide”, 12 entries
- “Maridebart cafraglutide”, 12 entries
- “AMG 133”, 6 entries
- “AMG 133 (frozen liquid)”, 1 entry
- “AMG 133 (liquid)”, 1 entry
Conditions, from the studies’ own filings
- Obesity, 23 studies
- Diabetes Mellitus, Type 2, 4 studies
- Atherosclerosis, 1 study
- Sleep Apnea, Obstructive, 1 study
- Liver Diseases, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.